Bergen, Norway, 27 August 2025 -- Lifecare ASA (LIFE), a MedTech company
developing next generation Continuous Glucose Monitoring (CGM) technology for
diabetes managment, announces that the second veterinary subject in its
ongoing longevity study (LFC-SEN-002) has confirmed the positive findings
observed in the first subject.
Summary:
* Data from second subject reconfirms safety, biocompatibility, and
suitability for long-term use in ongoing veterinary study LFC-SEN-002.
* Study results build on earlier human data confirming accurate glucose
measurement (LFC-SEN-001).
* Longevity study LFC-SEN-002 is still ongoing and planned to continue under
extended approval.
* Recent media events force the company to safeguarding shareholder trust
through a PFU filing.
Reference is made to Lifecares press release 8 November 2024. The purpose of
LFC-SEN-002 is to evaluate sensor efficacy for glucose measurement in dogs and
to document longevity, tolerability, and biocompatibility. The previous human
study (LFC-SEN-001) demonstrated glucose measurement performance on par with
commercially available CGM systems.
The ongoing veterinary longevity study (LFC-SEN-002) focuses on product
development aspects, including electronic performance, signal range, radio and
Bluetooth connectivity, and power consumption under real-life conditions.
Following 90 days of implantation, histopathological analyses performed by the
Norwegian University of Life Sciences (NMBU) confirmed that the device was
well tolerated, showing only mild localized tissue reactions consistent with a
normal foreign-body response. Importantly, no adverse events were observed,
reinforcing evidence that Lifecare's CGM device is safe and biocompatible for
long-term implantation.
The current approval for veterinary studies expires at the end of August.
Lifecare has already resubmitted the protocol to secure a continued approval,
as LFC-SEN-002 will continue until the company formally defines study end.
Additional subjects are planned for enrolment, expanding the scope beyond
longevity and tolerability to further validate glucose measurement performance
in both healthy and diabetic animals.
Safeguarding shareholder trust throug transparency
In addition to disclosure of positive and re-confirmative study data, this
announcement addresses recent media coverage that was based on information
Lifecare had refuted with documentation, prior to publication. This media
coverage was speculative, inaccurate, and strongly misleading, undermining
confidence in the company's technology and communication. This false,
misleading and inaccurate coverage seems to have directly affected the
company's market valuation.
As a publicly listed company, Lifecare has a duty to protect its shareholders
by ensuring that accurate and reliable information reaches the market. To
safeguard this principle, the company will file a formal complaint with the
Norwegian Press Complaints Commission (Pressens Faglige Utvalg, PFU). In
Lifecare's view, the coverage in question failed to meet basic press ethics
standards of accuracy and fairness.
Lifecare regards this as a matter of principle---both to protect shareholder
value and to uphold trust in transparent market communication.
The company reiterates its strong belief in the future of its technology and
its ability to deliver meaningful innovation for people living with diabetes.
Entering a defining phase, Lifecare moves forward with confidence ---
supported by proven results, a solid strategy, and a committed team.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is suitable for identifying and monitoring the occurrence of a wide
range of analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42